Advertisement
Australia markets close in 4 hours 21 minutes
  • ALL ORDS

    7,985.60
    +33.30 (+0.42%)
     
  • ASX 200

    7,713.80
    +31.40 (+0.41%)
     
  • AUD/USD

    0.6626
    +0.0000 (+0.00%)
     
  • OIL

    78.74
    +0.26 (+0.33%)
     
  • GOLD

    2,333.70
    +2.50 (+0.11%)
     
  • Bitcoin AUD

    96,488.47
    -407.90 (-0.42%)
     
  • CMC Crypto 200

    1,368.97
    +56.34 (+4.29%)
     
  • AUD/EUR

    0.6153
    +0.0007 (+0.11%)
     
  • AUD/NZD

    1.1019
    -0.0001 (-0.01%)
     
  • NZX 50

    11,781.41
    -39.37 (-0.33%)
     
  • NASDAQ

    18,093.57
    +202.77 (+1.13%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • Dow Jones

    38,852.27
    +176.59 (+0.46%)
     
  • DAX

    18,175.21
    +173.61 (+0.96%)
     
  • Hang Seng

    18,554.63
    -23.67 (-0.13%)
     
  • NIKKEI 225

    38,569.14
    +333.07 (+0.87%)
     

Spexis to host business update conference call on October 9, 2023

Spexis AG
Spexis AG

ALLSCHWIL, Switzerland, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced today that it will host a business update conference call on October 9, 2023, at 8.30am EDT.

Jeffrey D. Wager, M.D. (CEO & Chairman) will provide strategic business and financial updates. To access the conference call please use the following details:

France: +33 0805102207
Germany: +49 0800-6647650
Italy: +39 800897553
Switzerland +41 0800-002063
United Kingdom +44 08082389064
United States +1 877-317-6789
International Toll Free +1 412-317-6789

ADVERTISEMENT

Event Title: Spexis AG – Business Update Conference Call

The conference call will also be available via webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=6s6eCE7g

After the call, a replay of the webcast will be available via the above link.

About Spexis

Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com.

For further information please contact:

For Investors:

Hernan Levett
Chief Financial Officer
Spexis AG.
+41 61 567 16 00
IR@spexisbio.com

Or

Stephen Jasper
Managing Director
Gilmartin Group
stephen@gilmartinir.com

For Media:

Dr. Stephan Feldhaus
Feldhaus & Partner
+41 79 865 92 56
feldhaus@feldhaus-partner.ch